Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

5/14/25 4:40:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $JNJ alert in real time by email

Johnson & Johnson (NYSE:JNJ) will participate in the Goldman Sachs 46^th Annual Global Healthcare Conference on Wednesday, June 11^th, 2025. Management will participate in a Fireside Chat at 3:20 p.m. Eastern Time.

This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

The audio webcast replay will be available approximately 48 hours after the webcast.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250514300396/en/

Media contact: [email protected]

Investor contact: [email protected]

Get the next $JNJ alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$JNJ

Date	Price Target	Rating	Analyst
11/13/2025	$230.00	Sector Outperform	Scotiabank
10/20/2025	$203.00	Neutral → Outperform	Daiwa Securities
10/3/2025	$212.00	Equal Weight → Overweight	Wells Fargo
9/23/2025	$206.00	Neutral → Buy	Guggenheim
7/23/2025		Hold → Buy	Erste Group
5/13/2025	$153.00	Outperform → Market Perform	Leerink Partners
12/10/2024	$166.00	Neutral	BofA Securities
11/15/2024	$190.00	Outperform	Wolfe Research

More analyst ratings

$JNJ
Press Releases

Fastest customizable press release news feed in the world

View All

U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*

Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with BRCA2-mutated mCSPC HORSHAM, Pa., Dec. 12, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone for the treatment of patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC).1 Patients with BRCA mutations often have more aggressive forms of prostate cancer leading to poor prognosis, rep

12/12/25 8:25:00 PM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Johnson & Johnson (NYSE:JNJ) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12th, 2026. Management will participate in a Fireside Chat at 11:15 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20251208077091/en/ Media contact: [email protected] Investor contact: [email protected]

12/8/25 4:25:00 PM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC

New data from Cohort 4 of the SunRISe-1 study show more than 95 percent of patients remained progression free at one year, with more than 92 percent not undergoing bladder removal Patients with this type of bladder cancer have limited choices beyond radical cystectomy, highlighting the need for newer therapies for bladder preservation RARITAN, N.J., Dec. 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study show treatment with gemcitabine intravesical system resulted in high one-year disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) rates in patients with Bacil

12/5/25 4:20:00 PM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

$JNJ
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

View All

July 21, 2023 - FDA Roundup: July 21, 2023

For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

7/21/23 4:02:23 PM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

5/5/22 4:51:11 PM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

8/18/21 1:06:11 PM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

$JNJ
Leadership Updates

Live Leadership Updates

View All

Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

9/25/25 4:15:00 PM ET

$JNJ

$RBOT

Biotechnology: Pharmaceutical Preparations

Health Care

Industrial Specialties

Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

9/8/25 6:17:00 PM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

Johnson & Johnson (NYSE:JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/ "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare inno

6/10/25 4:51:00 PM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

$JNJ
Financials

Live finance-specific insights

View All

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025

Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2025 of $1.30 per share on the company's common stock. The dividend is payable on December 9, 2025 to shareholders of record at the close of business on November 25, 2025. The ex-dividend date is November 25, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquel

10/14/25 6:30:00 AM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business

Strengthens focus of Johnson & Johnson as an innovation powerhouse and accelerates the portfolio shift of its MedTech Segment to higher-growth and higher-margin markets Standalone orthopaedics business would operate as DePuy Synthes and be the largest, most comprehensive orthopaedics-focused company in the world Namal Nawana appointed to serve as Worldwide President of DePuy Synthes Johnson & Johnson (the "Company") (NYSE:JNJ) today announced the Company's intent to separate its Orthopaedics business to enhance the strategic and operational focus of each company and drive value for stakeholders. The intended separation would further strengthen the focus of Johnson & Johnson as an in

10/14/25 6:21:00 AM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook

2025 Third-Quarter reported sales growth of 6.8% to $24.0 Billion with operational growth of 5.4%* and adjusted operational growth of 4.4%* 2025 Third-Quarter reflects earnings per share (EPS) of $2.12 and adjusted EPS of $2.80 Significant innovation including approvals of INLEXZO for high-risk non-muscle invasive bladder cancer and TREMFYA subcutaneous in ulcerative colitis, submission of icotrokinra for plaque psoriasis, landmark data for RYBREVANT plus LAZCLUZE overall survival in non-small cell lung cancer, and DanGer Shock long-term survival benefit of Impella Heart Pump Company increases full year estimated reported sales5 guidance to $93.7B or 5.7% at the midpoint; reaffirm

10/14/25 6:20:00 AM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$JNJ

Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$JNJ

$JNJ
Analyst Ratings

Scotiabank initiated coverage on Johnson & Johnson with a new price target

Johnson & Johnson upgraded by Daiwa Securities with a new price target

Johnson & Johnson upgraded by Wells Fargo with a new price target

$JNJ
Insider Trading

SEC Form 4 filed by Director Woods Eugene A.

SEC Form 4 filed by Director Hewson Marillyn A

SEC Form 4 filed by Director Pinto Daniel E

$JNJ
Press Releases

U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*

Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC

$JNJ
FDA approvals

July 21, 2023 - FDA Roundup: July 21, 2023

May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

$JNJ
SEC Filings

SEC Form 13F-HR filed by Johnson & Johnson

SEC Form 10-Q filed by Johnson & Johnson

Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

$JNJ
Insider Purchases

Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

$JNJ
Leadership Updates

Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

$JNJ
Financials

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025

Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business

Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook

$JNJ
Large Ownership Changes

SEC Form SC 13G filed by Johnson & Johnson

SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $JNJ

Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $JNJ

$JNJ Analyst Ratings

Scotiabank initiated coverage on Johnson & Johnson with a new price target

Johnson & Johnson upgraded by Daiwa Securities with a new price target

Johnson & Johnson upgraded by Wells Fargo with a new price target

$JNJ Insider Trading

SEC Form 4 filed by Director Woods Eugene A.

SEC Form 4 filed by Director Hewson Marillyn A

SEC Form 4 filed by Director Pinto Daniel E

$JNJ Press Releases

U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*

Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC

$JNJ FDA approvals

July 21, 2023 - FDA Roundup: July 21, 2023

May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

$JNJ SEC Filings

SEC Form 13F-HR filed by Johnson & Johnson

SEC Form 10-Q filed by Johnson & Johnson

Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

$JNJ Insider Purchases

Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

$JNJ Leadership Updates

Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

$JNJ Financials

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025

Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business

Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook

$JNJ Large Ownership Changes

SEC Form SC 13G filed by Johnson & Johnson

SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

Recent Analyst Ratings for
$JNJ

Recent Analyst Ratings for
$JNJ

$JNJ
Analyst Ratings

$JNJ
Insider Trading

$JNJ
Press Releases

$JNJ
FDA approvals

$JNJ
SEC Filings

$JNJ
Insider Purchases

$JNJ
Leadership Updates

$JNJ
Financials

$JNJ
Large Ownership Changes